Andrew R. Saik's most recent trade in Arvinas Inc was a trade of 5,700 Common Stock done at an average price of $7.6 . Disclosure was reported to the exchange on June 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arvinas Inc | Andrew R. Saik | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.61 per share. | 24 Jun 2025 | 5,700 | 164,401 (0%) | 0% | 7.6 | 43,377 | Common Stock |
| Milestone Pharmaceuticals Inc | Andrew R. Saik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew R. Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 91,000 | 91,000 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew R. Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 59,600 | 170,101 (0%) | 0% | 0 | Common Stock | |
| Arvinas Inc | Andrew Saik R. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 74,960 | 74,960 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew Saik R. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 49,092 | 110,501 (0%) | 0% | 0 | Common Stock |